Related Experiment Video
Updated: Aug 12, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Retinopathy of prematurity and surfactant treatment
R Axer-Siegel1, M Snir, A Ma'ayan
1Department of Ophthalmology, Beilinson Medical Center, Petah Tiqva, Israel.
Insights
Surfactant therapy for premature infants did not increase the risk of retinopathy of prematurity (ROP). This study found no significant difference in ROP incidence between treated infants and historical controls.
Area of Science:
- Neonatal ophthalmology
- Perinatal medicine
- Respiratory distress syndrome research
Background:
- Surfactant therapy improves outcomes for premature infants with respiratory distress syndrome (RDS).
- The impact of surfactant therapy on retinopathy of prematurity (ROP) remains unclear.
- Potential risks include increased PaO2 and survival of low-birth-weight infants, while benefits may stem from improved health.
Purpose of the Study:
- To investigate the association between surfactant therapy and the incidence and severity of ROP in premature infants.
- To compare ROP outcomes in surfactant-treated infants versus historical controls.
Main Methods:
- Retrospective review of ophthalmologic examinations in a neonatal intensive care unit.
- Comparison of premature infants (<32 weeks gestation, <1500g birth weight) receiving surfactant with historical controls not receiving surfactant.
Main Results:
- ROP was observed in 65% of surfactant-treated infants (n=20) and 77% of controls (n=25).
- Threshold ROP requiring treatment occurred in 30% of treated infants and 40% of controls.
- The observed differences in ROP incidence and severity were not statistically significant.
Conclusions:
- Surfactant therapy was not associated with a statistically significant increase in ROP incidence in this cohort.
- Further research may be needed to fully elucidate the complex relationship between surfactant therapy and ROP.
Purpose:
Surfactant therapy in premature infants has reduced the severity of respiratory distress syndrome (RDS), thus leading to a reduction in mortality. However, the anticipated effect of surfactant therapy on the incidence and severity of retinopathy of prematurity (ROP) is ambiguous. The acute rise in PaO2 and the increased survival of low-birth-weight infants may augment the risk of ROP, whereas their improved health and respiratory status may lower it.
Methods:
We reviewed the findings of sequential ophthalmologic examinations performed in our neonatal intensive care unit. Premature infants of gestational age under 32 weeks and weighing less than 1500 g at birth who received surfactant treatment were compared with a group of historical controls consisting of premature infants of the same mean birth weight and gestational age who did not get this supplement.
Results:
ROP was present in 13 (65%) of the 20 surfactant-treated babies, and threshold disease was noted in six (30%). In the historical control group, 20 (77%) of 25 infants had ROP, of whom 10 (40%) were treated for threshold disease. These differences were not statistically significant.
Conclusion:
Surfactant therapy was not associated with an increased incidence of ROP in our series.
Related Concept Videos
Breathing
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Diabetic Retinopathy

